Ravi Karra: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

• The congress is free to attend.
• Register via the link.

Co-Chair of VIRO

Images

Name

Rana McKay Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on  “Future Directions: Emerging Agents and Combinations.” She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Ravi Karra

Dr. Ravi Karra is the Vice President of Oncology at Advanced Clinical, a global clinical development and strategic resourcing organization.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Karra will participate in the panel discussion titled “Evidence-Based Approaches to Variant Histologies.” His contributions will focus on:

• Integrating translational research data, including molecular and imaging biomarkers, into clinical trial design.
• Overcoming challenges related to rare and variant histologies in oncology trials.
• Enhancing precision oncology through evidence-based medicine and innovative trial methodologies.
• Sharing perspectives from a global clinical development and resourcing standpoint to improve patient outcomes.

Dr. Karra’s leadership role and deep experience in oncology clinical trials position him as a key voice in advancing evidence-based approaches to renal cell carcinoma variant histologies.

Global Voices in Renal Oncology (VIRO) 2025